[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:folh1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"FOLH1 Gene",39,29,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,162,169,175,181,187,194,201,207,213,220,225,231,237,244],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06096870","Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy",[12],"Phase 2","RECRUITING","2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.930066Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05413850","Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:18.747857Z","2026-07-05T05:32:16.802272Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06520345","The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)",[27],"Phase 3","2026-08-26T02:16:08.402952Z","2026-07-05T05:32:16.759187Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06531499","A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study",[34],"Phase 1","2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.662642Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT06084338","Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc",[12],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.536969Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05939414","An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.",[27],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:29.053016Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06738303","Cabazitaxel +\u002F- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer",[12],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:29.025195Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07258407","A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer",[20],"2026-08-26T02:17:24.721169Z","2026-05-05T02:43:28.964236Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07054346","Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617",[34],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:28.883528Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06200103","Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer",[12],"2026-08-03T02:58:35.674064Z","2026-05-05T02:43:27.981408Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06852820","68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:27.635884Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06044857","PSMA PET Response Guided SabR in High Risk Pca",[34],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.600224Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04868604","64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)",[20],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:27.503334Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06039371","Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study",[12],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:27.317483Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07237269","Abi\u002FPred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer",[12],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.281899Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07285694","AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)",[20],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:27.276928Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06632977","Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial",[12],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.248700Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07150715","Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma",[12],"2026-08-26T02:17:03.534765Z","2026-05-05T02:43:27.041457Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07476001","Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC",[12],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:26.905282Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07234981","PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:35:31.778059Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06574880","STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer",[20],"2026-08-26T02:18:00.873391Z","2026-05-05T02:35:31.742674Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT07223034","A Study of 177Lu-PSMA-617 in People With Gliomas",[34],"2026-08-26T02:16:23.080181Z","2026-07-05T05:32:16.669055Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06444412","An Investigational Scan (Ga-68 PSMA-11 PET\u002FCT) for Detection of Disease Recurrence or Progression in Patients With Glioma",[12],"2026-08-26T02:18:17.007929Z","2026-07-05T05:32:16.753250Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06062745","Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET\u002FCT",[34],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:29.197963Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":107,"content_modified":161},"NCT06855277","Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC",[27],"2026-05-05T02:43:28.482664Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":167,"content_modified":168},"NCT06099093","Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan",[166],"Phase 4","2026-08-26T02:18:53.782384Z","2026-05-05T02:43:28.366482Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06736054","A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer",[34],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:27.745995Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT04167969","The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer",[34],"2026-08-26T02:18:46.137046Z","2026-04-29T02:57:57.120292Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT05435495","Mechanisms of Resistance to PSMA Radioligand Therapy",[],"2026-08-26T02:19:11.399072Z","2026-05-29T15:36:40.173358Z",{"nct_id":188,"title":189,"phases":190,"status":191,"updated_at":192,"content_modified":193},"NCT07650240","Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial",[12],"NOT_YET_RECRUITING","2026-08-26T02:17:38.215063Z","2026-06-17T02:29:30.058877Z",{"nct_id":195,"title":196,"phases":197,"status":191,"updated_at":199,"content_modified":200},"NCT07609225","Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy",[198],"Early Phase 1","2026-08-26T02:18:23.582895Z","2026-05-29T15:36:40.226787Z",{"nct_id":202,"title":203,"phases":204,"status":191,"updated_at":205,"content_modified":206},"NCT07550517","PSMA-High: EBRT\u002F PSMA617\u002F ADT vs. EBRT\u002F ADT",[12],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:29.585469Z",{"nct_id":208,"title":209,"phases":210,"status":191,"updated_at":211,"content_modified":212},"NCT07593079","Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer",[12],"2026-08-26T02:16:16.169331Z","2026-05-29T15:36:40.203005Z",{"nct_id":214,"title":215,"phases":216,"status":191,"updated_at":218,"content_modified":219},"NCT07725523","Phase IIb Trial to Investigate the Safety and Efficacy of OTL78 Injection (Zopocianine)",[217],"Phase 2\u002FPhase 3","2026-08-26T02:16:31.714843Z","2026-07-30T01:46:14.446753Z",{"nct_id":221,"title":222,"phases":223,"status":191,"updated_at":14,"content_modified":224},"NCT07682649","Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer",[34],"2026-07-19T19:36:05.146565Z",{"nct_id":226,"title":227,"phases":228,"status":191,"updated_at":229,"content_modified":230},"NCT07698535","Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial",[12],"2026-08-26T02:17:16.980188Z","2026-07-19T19:36:05.080439Z",{"nct_id":232,"title":233,"phases":234,"status":191,"updated_at":235,"content_modified":236},"NCT07635524","A Phase 2 Trial of 61Cu-NU101 PET\u002FCT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET\u002FCT.",[12],"2026-08-26T02:19:27.519777Z","2026-06-14T18:39:22.253038Z",{"nct_id":238,"title":239,"phases":240,"status":241,"updated_at":242,"content_modified":243},"NCT05160480","A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:24.494016Z","2026-06-16T05:54:08.025989Z",{"nct_id":245,"title":246,"phases":247,"status":248,"updated_at":249,"content_modified":250},"NCT06849544","Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:19:54.166214Z","2026-05-05T02:43:27.109669Z"]